Arcus biosciences to present data from ongoing edge-gastric study at asco plenary and to report third-quarter financial results on november 7

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus) today announced that data from cohort a1 of the ongoing phase 2 edge-gastric study will be presented at the american society of clinical oncology (asco) monthly plenary series on november 7, 2023. edge-gastric (also known as arc-21), a collaboration between arcus and gilead sciences, is a phase 2 platform study evaluating various combinations of domvanalimab, an fc-silent anti-tigit monoclonal antibody, and zimberelimab, an a.
RCUS Ratings Summary
RCUS Quant Ranking